Table 2.

Summary of completed studies with available results on ClinicalTrials.gov (n=14)

ClinicalTrials.gov Identifier	Intervention	Phase	Study population	Completion date	Location	Ethnicity and race of study population, %
NCT00294554	Memantine		PDD, n=20	December 2008	Maryland (US)	Race: White- 100%
NCT00543855[125]	Donepezil hydrochloride	2	Probable DLB, n=139	February 2010	Japan	Not reported
NCT00623103[126]	Rivastigmine	3	PDD, n=359	November 2010	Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kansas, New York, Ohio, Pennsylvania, Texas, Utah, Washington (US); Argentina; Australia; Austria; Belgium; Canada; France; Germany; Italy; Netherlands; Spain; Turkey; United Kingdom	Not reported
NCT02708186[127]	Nelotanserin	2	Lewy body dementia with REM sleep behavior disorder, n=34	November 2010	Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Indiana, Kansas, Nebraska, North Carolina, North Dakota, Ohio, Rhode Island, Tennessee, Texas (US)	Race: Asian- 2.9% White- 97.1%
NCT00598650[128]	Donepezil hydrochloride	2	Probable DLB, n=108	March 2011	Japan	Not reported
NCT00988117	Rivastigmine	4	PD-MCI, n=6 PDD, n=6 Controls, n=15	April 2011	California (US)	Not reported
NCT01023672	Armodafinil	4	Probable DLB, n=17	March 2012	Minnesota (US)	Not reported
NCT01785628[129]	Sarcosine		PDD, n=30	July 2012	Taiwan	Not reported
NCT01278407[130]	Donepezil	3	Probable DLB, n=138	April 2013	Japan	Not reported
NCT02258152	Landipirdine	2	PDD, n=82	October 2017	Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kansas, Maryland, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania, South Carolina, Texas (US)	Ethnicity: Non-Hispanic- 98.8% Unknown- 1.2%
						Race: Black or African American- 1.2% White- 98.8%
NCT02669433[131]	Intepirdine	2	Probable DLB, n=268	December 2017	Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts, Minnesota, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Virginia (US); Canada; France; Italy; Netherlands; Spain; United Kingdom	Ethnicity: Hispanic- 3.7% Non-Hispanic- 95.1% Unknown- 1.1%
						Race: Asian- 1.5% Black or African American- 1.5% White- 95.5% More than one race- 0.4% Unknown- 1.1%
NCT04001517[132]	Neflamapimod	2	Probable DLB, n=91	June 2020	California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, Nevada, New York, North Carolina, Ohio, Oregon, Pennsylvania, Virginia, Washington (US); Netherlands	Ethnicity: Hispanic- 7.7% Non-Hispanic- 92.3%
						Race: Black or African American- 1.1% White- 98.9%
NCT03305809[133]	Mevidalen	2	Lewy body dementia, n=344	July 2020	Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Kansas, Maine, Massachusetts, Michigan, Missouri, Nevada, New Hampshire, New Jersey, Ney York, North Carolina, Pennsylvania, South Carolina, Texas, Virginia, Washington, Wisconsin (US); Canada; Puerto Rico	Ethnicity: Hispanic- 9.6% Non-Hispanic- 89.8% Unknown- 0.6%
						Race: American Indian or Alaska Native- 0.6% Asian- 1.2% Black or African American- 3.2% White- 94.8% More than one race- 0.3%
NCT04764669	Irsenontrine	2	Probable DLB, n=21 Probable PDD, n=13	January 2022	Arizona, Florida, Kentucky, New Jersey, New York, Ohio, Oregon (US); Canada	Ethnicity: Hispanic- 8.8% Non-Hispanic- 91.2%
						Race: American Indian or Alaska Native- 2.9% White- 97.1%

PD-MCI: Parkinson’s disease with mild cognitive impairment; PDD: Parkinson’s disease dementia; DLB: dementia with Lewy bodies. Individual states are listed for United States, reporting of one country other than United States does not imply a single site study. Ethnicity and race data is presented as reported in ClinicalTrials.gov. For those without available data on ClinicalTrials.gov, ethnicity or race data were also not available on cited publications.